9 articles reviewed and scored below the CED clinical relevance threshold of 40. Organized by topic below. Some may still be relevant to your situation.
Research
(2 articles)
ResearchPolicy
WSU and UW researchers will share cannabis research in Pullman | Green Zone
Researchers from Washington State University and the University of Washington will present cannabis research findings at a dedicated event in Pullman this spring. The submission deadline for faculty and student researchers to present their work has just closed.
Academic institutions in Washington are creating dedicated forums for cannabis research presentation and collaboration between university researchers.
ResearchPolicySafety
International Research Community for Tobacco and Nicotine Honors Roswell Park Leader
Researchers from Roswell Park Comprehensive Cancer Center presented findings on concurrent cannabis and tobacco use patterns from the International Tobacco Control Four Country Survey, examining smoking and vaping behaviors across multiple populations. The study provides epidemiological data on how cannabis co-use practices vary among tobacco and nicotine users in different geographic regions.
The International Tobacco Control survey reveals important patterns in how cannabis use intersects with tobacco and nicotine consumption, offering evidence-based insights into polysubstance use behaviors across diverse populations.
Anxiety
(1 article)
AnxietyMental HealthResearch
Experiences with marijuana? Please share : r/OCD – Reddit
A Reddit discussion thread explores personal experiences with marijuana use among individuals with obsessive-compulsive disorder, with users reporting varied outcomes ranging from symptom exacerbation to perceived relief. The conversation raises questions about how cannabis interacts with OCD symptoms and whether it may worsen or improve the condition for different users.
Individual reports on cannabis and OCD outcomes vary considerably, suggesting that neurobiological responses to cannabinoids may differ significantly based on OCD presentation and underlying neurochemistry.
Safety
(1 article)
SafetyPolicyPediatrics
Bill to require stricter packaging requirements for marijuana edibles dies in Oregon legislature
A proposed Oregon bill requiring individual wrapping of cannabis edibles and standardized dosing per piece failed to advance in the legislature. The legislation aimed to improve product safety and prevent accidental consumption, particularly among children.
Oregon’s failed edible packaging bill would have mandated individual wrapping and uniform dosing for THC-containing products, addressing long-standing concerns about accidental pediatric exposures and product safety standardization.
Policy
(5 articles)
PolicyResearch
Ricketts addresses Congress leaving Nebraska off list protecting state medical cannabis laws
U.S. Senator Pete Ricketts avoided directly answering whether he supports adding Nebraska to a congressional list that protects state medical cannabis laws from federal interference. The senator’s response highlights ongoing tensions between state-level medical cannabis programs and federal policy positions.
Senator Ricketts’ avoidance of a direct answer on Nebraska’s inclusion in federal medical cannabis protections reflects the political complexity surrounding state versus federal cannabis regulation.
PolicySafetyIndustry
A Frightening Florida Medical Cannabis Market
Florida’s medical cannabis market faces significant regulatory and safety challenges that threaten patient access and product quality. The state’s rapid expansion and loose oversight have created concerning conditions for consumers seeking reliable therapeutic cannabis options.
Florida’s medical cannabis market demonstrates how inadequate regulatory frameworks can compromise patient safety and market integrity when commercial growth outpaces clinical oversight.
PolicyHempTHC
Intoxicating Hemp Ban Unchanged in 2026 Farm Bill’s Advancement
The 2026 Farm Bill maintains the federal ban on intoxicating hemp products, including those containing delta-8 THC and HHC cannabinoids, despite bipartisan efforts to achieve repeal. The regulatory restriction continues to define legal hemp as cannabis containing no more than 0.3% THC by dry weight, preserving existing limitations on synthetic and naturally-derived intoxicating cannabinoids.
The advancement of the 2026 Farm Bill without modification to intoxicating hemp restrictions suggests federal policy remains aligned with limiting access to delta-8 THC and other psychoactive cannabinoid products despite ongoing legislative advocacy for change.
PolicyHempTHC
Wisconsin hemp growers, sellers brace for new federal hemp law – WPR
Wisconsin hemp growers and sellers are preparing for compliance with new federal hemp regulations that will restrict products containing THC and its variants including THC-A and delta-9 THC. The changes pose significant challenges for businesses whose products currently fall within regulatory gray areas between legal hemp and controlled substances.
New federal hemp regulations targeting THC variants are creating compliance uncertainty for Wisconsin producers operating in the space between federally legal hemp and controlled marijuana products.
PolicySafety
Guns and ganja: Supreme Court skeptical of federal law banning firearm possession for … – Reddit
The Supreme Court is questioning the constitutionality of federal law that prohibits firearm ownership for individuals with marijuana convictions, raising questions about how cannabis criminalization intersects with Second Amendment rights. The case highlights historical racial disparities in cannabis enforcement and whether such restrictions remain justified under current policy.
The Supreme Court’s skepticism toward the federal firearm ban for cannabis offenders reflects broader tensions between outdated drug policies and constitutional protections, particularly given the disparate enforcement history targeting Black Americans.
Digest-Level Clinical Commentary
Clinical Reflection
These digest items signal that cannabis medicine practitioners must navigate an increasingly fragmented regulatory landscape where federal-state misalignments (hemp THC limits, medical cannabis protections, firearm restrictions) create clinical and medicolegal complexity for patient care. The emerging safety concerns in rapidly expanding markets like Florida, combined with persistent gaps in pediatric protection standards, underscore that evidence-based dosing guidance and careful product verification have become essential clinical competencies alongside traditional prescribing knowledge. Most concerning is the absence of robust clinical research in this digest relative to policy and safety items, suggesting that clinical practice continues to outpace the generation of high-quality data needed to optimize patient outcomes and mitigate harm.
Clinical Perspective
These articles reflect a regulatory landscape in transition, where policy changes and enforcement gaps are creating practical challenges for patient safety and clinical care. Key concerns include inadequate product oversight (particularly in rapidly expanding markets like Florida), evolving federal restrictions on hemp-derived products that may confuse patients about legal options, and persistent gaps in pediatric safety protections. Clinicians should remain informed about their state’s regulatory environment and counsel patients accordingly, particularly regarding product standardization and the distinction between federally compliant and gray-market cannabis products.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
